RxDoctor Payments Data

John Graham, MD

Family Medicine · Greenbrae, CANPI 1306836366

Payments from drug & device makers

$3,361in general payments, 2019–2025

Across 44 payments — averaging $76.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • GSK$305
  • AstraZeneca$129
  • Boehringer Ingelheim$78
  • Lilly USA, LLC$55
  • Insmed, Inc.$40
  • plus $90 from 4 others

What the payments were for

  • Consulting fees$2,65079%
  • Food & beverage$71121%

General payments by program year

19
20
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)3$2,664
GSK22$305
AstraZeneca7$129
Boehringer Ingelheim3$78
Lilly USA, LLC3$55
Insmed, Inc.2$40
Amgen1$29
Astellas Pharma US Inc1$24
Novo Nordisk1$22
Merck1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,361 in reported general payments places this provider in the 85th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$270,581
Medicare patients
500
Services billed
3,050

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide37$44,025
JardianceEmpagliflozin17$24,104
TrulicityDulaglutide11$16,174
EliquisApixaban15$14,421
MounjaroTirzepatide13$12,968
OxycontinOxycodone Hcl21$6,118
Gabapentin129$4,079
Atorvastatin Calcium172$2,006
Levothyroxine Sodium136$1,849
Bupropion XlBupropion Hcl47$1,763
Azelastine Hcl22$1,622
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen79$1,618
Amlodipine Besylate93$1,096
Celecoxib16$1,071
Omeprazole59$1,063

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$22$44,02537 claims
Lilly USA, LLCTrulicity, Mounjaro$55$29,14224 claims
Boehringer IngelheimJardiance$78$24,10417 claims
AbbVieSynthroid$2,664$53923 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,533 family medicine providers in California.

Other family medicine in Greenbrae

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →